Amprius Q3 revenue up 83% to $39.1M; net loss narrows to $3.5M, but key catalysts remain unproven.

What happened

Amprius Technologies reported Q3 2026 revenue of $39.1 million, up 83% year over year and up sequentially from $34.0 million in Q2, while net loss attributable to common stockholders narrowed to $3.5 million from $3.9 million a year ago. The results extend the company's rapid commercialization of silicon-anode batteries for drones and aviation, with revenue growth consistent with management's raised 2026 guidance of at least $140 million. However, the press release does not disclose gross margin, cash flow, or working capital details, leaving open the question of whether profitability improvement is sustainable or simply a function of volume timing. Crucially, the release provides no update on SiCore500 commercial shipments, repeat defense or drone orders, or progress on the U.S. pouch-cell qualification timeline, which are the key catalysts identified in the prior analysis. As a result, the stock remains in a 'show-me' period where revenue growth alone is insufficient to confirm the domestic manufacturing and repeat-order thesis.

Implication

The 83% revenue growth confirms demand for Amprius's high-energy-density cells, but without gross margin or cash flow data, the quality of that growth is unverified. The stock's current price of $7.58 remains below the base-case implied value of $8.50, but the gap is not wide enough to compensate for unresolved execution risks. Investors should monitor the next quarterly filing for signs of working capital stabilization, because persistent receivables and inventory growth could signal channel stuffing or poor cash conversion. The critical near-term events remain SiCore500 commercial shipments expected in Q4 2026 and any disclosure of additional obligated government funding beyond the initial $22 million. Until those milestones are met, the stock is likely to remain range-bound, and the more attractive entry point remains around $6.25 per the prior analysis.

Thesis delta

The Q3 results are in line with the existing positive commercialization trend but do not alter the core thesis. The investment case still hinges on proving SiCore500 manufacturability and U.S. line qualification, and the press release offers no new evidence on those fronts. Therefore, the WAIT rating remains appropriate with no material shift in conviction.